Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04073316
Other study ID # 2019-000794-23
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 13, 2020
Est. completion date February 2023

Study information

Verified date July 2022
Source University Hospital, Angers
Contact Cédric ANNWEILER, MD, PhD
Phone +33 2 41 35 54 86
Email cedric.annweiler@chu-angers.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the change of global cognitive performance after 52 weeks of intervention among participants with nonvalvular atrial fibrillation (NVAF) receiving rivaroxaban versus a vitamin K antagonist (warfarin). The secondary objectives are to compare, among participants with NVFA receiving rivaroxaban versus warfarin : - the changes of global cognitive performance after 26 weeks of intervention - the changes of executive functions after 26 and 52 weeks of intervention - the changes of episodic memory after 26 and 52 weeks of intervention - the changes of independence and autonomy after 26 and 52 weeks of intervention


Description:

Detailed Description: Vitamin K antagonists (VKAs) are commonly used for their role in hemostasis by interfering with vitamin K cycle decreasing the bioavailability of the vitamin K active form. In addition to a role in blood coagulation, vitamin K participates in brain health and function by regulating the synthesis of sphingolipids, a constituent of the myelins sheath and the neurons membrane, and through the biological activation of vitamin K-dependent proteins (VKDPs) involved in neuron survival. Epidemiological studies have reported a positive association between higher serum vitamin K concentration and better verbal episodic memory performance in older adults, and an inverse association between dietary vitamin K intakes and behavioural disorders and cognitive complaint. The clinical implication is that the use of VKAs, which deplete the active form of vitamin K, may be responsible for Central Nervous System (CNS) disorders. CNS abnormalities were observed in newborns exposed in utero to VKA. Similarly, the investigators and other researchers reported that the use of VKAs (especially fluindione) was directly associated with cognitive decline (notably executive dysfunction) and hippocampal atrophy in older adults, even while taking into account the history of atrial fibrillation, stroke and vascular brain changes. These cross-sectional and longitudinal studies were yet limited by their observational design. Clinical trials are now warranted to explore the effect on cognition of VKAs against direct oral anticoagulants (DOACs), whose indications are similar but whose mechanism does not interfere with vitamin K. The favorable impact of the use of DOACs compared to VKA in the incidence of dementia was also observed in a US retrospective population-based study of patients managed per routine clinical care. The investigators hypothesize that VKAs have a deleterious impact on cognition and brain morphology compared to DOACs, due to the decrease in vitamin K bioavailability. A review of the published clinical trials comparing the effects of VKAs and DOACs, especially rivaroxaban, shows that cognition and brain volume were not assessed as outcomes in these trials.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date February 2023
Est. primary completion date February 2023
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: - Men or women = 70 years old - Newly diagnosed hemodynamically stable NVAF longer than 52 hours or of unknown duration, and CHA2DS2-VASc score according to ESC 2016 guidelines for anticoagulation treatment indications - MMSE score = 20 - Subjects who can give written consent to participate in the study - Affiliation to a social security scheme. Exclusion Criteria: - Known history of stroke and/or a diagnosed condition of dementia (DSM-IV criteria) and/or severe depressive symptomatology (score on the 4-item Geriatric Depression Scale > 3) - Moderate or severe mitral stenosis - Conditions other than NVAF that require anticoagulation - Use of anticoagulant more than 3 days at inclusion or more than 15 days in the preceding 12 months - Regular use of antiplatelet medications and/or nonsteroidal anti-inflammatory agents and/or azole class of antifungal agents and/or inhibitor of HIV protease - Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to randomization - Known presence of cardiac thombus or myxoma or valvular atrial fibrillation - Any contraindication to anticoagulation, high risk of bleeding, and any other contraindication listed in the local labeling for the experimental treatment and comparator treatment - Unstable health, severe hepatic failure, or severe and moderate renal failure (creatinine clearance <50 mL/min), acute coronary syndromes - Participation in another simultaneous clinical trial - Inability to understand and speak French - Refusal to participate from the participant - Persons deprived of their liberty by administrative or judicial decision, persons under psychiatric care under duress, adults subject to a legal protection measure or unable to express their consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rivaroxaban 20 MG
Rivaroxaban intake, 20mg/day
Warfarin
Warfarin intake, with target INR range between 2 and 3

Locations

Country Name City State
France Angers University Hospital Angers

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Angers Bayer

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in global cognitive performance Global cognitive performance is assessed with Alzheimer's Disease Assessment Scale-cognition score (ADAS-cog).
Total scores range from 0-70, with higher scores (= 18) indicating greater cognitive impairment.
This outcome is assessed at baseline, 26 and 52 weeks after inclusion.
Secondary Change in executive functions Executive functions are assessed with Frontal Assessment Battery score (FAB). This outcome is assessed at baseline, 26 and 52 weeks after inclusion.
Secondary Change in executive functions Executive functions are assessed with digit spans. This outcome is assessed at baseline, 26 and 52 weeks after inclusion.
Secondary Change in executive functions Executive functions are assessed with Trail Making Tests (TMT) parts A and B. This outcome is assessed at baseline, 26 and 52 weeks after inclusion.
Secondary Change in executive functions Executive functions are assessed with Stroop test. This outcome is assessed at baseline, 26 and 52 weeks after inclusion.
Secondary Change in executive functions Executive functions are assessed with the Processing Speed Index. This outcome is assessed at baseline, 26 and 52 weeks after inclusion.
Secondary Change in episodic memory Episodic memory is assessed with Five-word test. The 5-word test studies the recall of a short list. The score of the first immediate recall and the score of the delayed recall should normally be equal to 10. This outcome is assessed at baseline, 26 and 52 weeks after inclusion.
Secondary Change in independence and autonomy Independence and autonomy are assessed with Activities of Daily Living (ADL) score.
ADL is an autonomy assessment grid (from 0 to 6) for basic activities of daily living (ADL).
The lower the score, the more dependent the patient is.
This outcome is assessed at baseline, 26 and 52 weeks after inclusion.
Secondary Change in independence and autonomy Independence and autonomy are assessed with the 4-item Instrumental Activities of Daily Living (IADL-PAQUID) score.
This test is used to assess the level of dependence in instrumental activities of daily living.
The scale ranges from 0 to 4, with 0 indicating total dysautonomy and 4 indicating a totally autonomous person.
This outcome is assessed at baseline, 26 and 52 weeks after inclusion.
See also
  Status Clinical Trial Phase
Recruiting NCT04586972 - Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;
Completed NCT02007655 - Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation
Completed NCT02674594 - Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US N/A
Recruiting NCT04494347 - Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR) N/A
Not yet recruiting NCT04942873 - The Adherence to Oral Anticoagulant in Chinese Patients With NVAF
Recruiting NCT05731882 - First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder N/A
Completed NCT01885598 - Eliquis Regulatory Post Marketing Surveillance N/A
Completed NCT02919982 - Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation
Completed NCT00684307 - Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation Phase 2
Completed NCT03374540 - Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
Recruiting NCT05715658 - Pharmacokinetic Study to Evaluate Dabigatran Etexilate in Elderly Subjects N/A